Bioinfra Co Ltd
199730
Company Profile
Business description
Bioinfra Co Ltd includes bioequivalence testing of generic drugs, Phase 1 clinical trials for improved new drugs, regulatory approval clinical trials, immunoassays, and pharmaceutical quality testing.
Contact
120 Heungdeokjungang-ro
4th and 5th Floors
Giheung-gu, Yongin-si
Gyeonggi-do16950
KORT: +82 316272800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
138
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
A tough year for jackpots however earnings are expected to normalise.
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,462.06 | 8.97 | 0.11% |
| DAX 40 | 26,060.96 | 77.92 | 0.30% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,770.74 | 22.58 | 0.21% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,641.16 | 66.82 | -0.87% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |